ClinicalTrials.gg
Not yet recruitingNCT06217913Updated Jan 23, 2024

Effects of Monitoring Blood Pressure During Pregnancy

An interventional study of wearable device to monitor the blood pressure in Birth Weight and Weight Gain Trajectory, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

In this study, at least 400 women with high-risk of pregnancy hypertension will use a wearable device to monitor the blood pressure during gestational age from 12 weeks to 28weeks. The observed outcomes including maternal and offspring. Participants were from three hospital including Shanghai Xinhua Hospital, Jiaxing Maternal and Child Health Hospital and Peking University Third Hospital. Pregnant women were randomly divided into control group (routine delivery examination group) and intervention group (routine delivery examination group + use of wearable blood pressure monitoring device group), 200 cases each.

02

Conditions studied

  • Birth Weight
  • Weight Gain Trajectory
03

In context

Birth Weight

185 studies on the registry are indexed under Birth Weight; 25 are open to participants now.

This study's planned enrollment of 400 is above the median of 170 across 117 interventional studies indexed under Birth Weight.

Browse Birth Weight studies →

Lead sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a single pregnancy before 12 weeks of pregnancy
  • The presence of any of the following risk factors: age > 30 years, a history of eclampsia, a family history of eclampsia, obesity ( ≥ 30 Kg/m2), and a history of gestational hyperglycemia (pregestational type 1 and type 2 diabetes; gestational manifest diabetes and gestational diabetes requiring insulin treatment), preexisting chronic hypertension, kidney disease, and diseases such as systemic lupus erythematosus and antiphospholipid syndrome.
  • Signed the can be continuously followed up.
  • Permanent population living in the study area.
  • All subjects received routine antenatal examination and treatment.

Exclusion criteria

Exclusion Criteria:

  • Termination of pregnancy before 20 weeks
  • Withdraw from the study
  • Lost visitors
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • No intervention
    control group

    routine delivery examination group

  • Experimental
    intervention group

    routine delivery examination group + use of wearable blood pressure monitoring device group

    Device: wearable device to monitor the blood pressure

Interventions

  • Devicewearable device to monitor the blood pressure

    Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.

06

What researchers measure

Primary outcomes

  1. Offspring weight change

    The offspring would be followed up from birth to 2 years of age at 42days, 3, 6, 12, 18 and 24 months of birth. Birth weights and weights would be measure in kilograms. The primary outcome the growth curve of the follow-up weights.

    Time frame: up to 24 months

Secondary outcomes

  1. Maternal blood pressure change

    24-hour weekly blood pressure and its fluctuation in pregnant women from 12 to 20 weeks of gestation would be measure in mmHg.

    Time frame: 16 weeks

  2. Maternal complications

    The incidence of hypertension in pregnancy, pre-eclampsia, eclampsia, placental abruption, transient ischemic attack or stroke, and HELLP syndrome, which would be stated in percentages.

    Time frame: 28 weeks

  3. Offspring outcomes

    Including incidence such as neonatal respiratory distress syndrome, sepsis, early-onset thrombocytopenia, early-onset neutropenia, hypoglycemia, congenital hypothyroidism, bronchopulmonary dysplasia, necrotizing enterocolitis, recurrent respiratory infections, infantile wheeze etc., which would be stated in percentages.

    Time frame: up to 24 months

  4. Offspring neurodevelopment

    Assessing neurodevelopment using ASQ scores or Bayley scores.

    Time frame: up to 24 months

  5. Offspring perinatal outcomes

    Including the incidence of mortality, large for large for gestational age infants and small for gestational age infants, which would be stated in percentages.

    Time frame: up to 24 months

Other outcomes

  1. metabolomics

    Meteranl metabolomics during pregnancy (around gestational age at 12 weeks and 28weeks) would be measured in pg/ml.

    Time frame: 16 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06217913
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jan 23, 2024

Study contacts

Dongying Zhao, MD,PhD
Contact
zdy0056374@aliyun.com
25078395
Yongjun Zhang, MD,PhD
Contact
zhangyongjun@sjtu.edu.cn
25078395

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion